EMJ Hematology 9 [Supplement 6] . 2021

In this issue

APPROXIMATELY 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapsed/refractory forms of the disease (R/R DLBCL). With effective forms of treatment currently lacking, there is an increasing need for the development of novel therapies to successfully treat the disease. This review provides a summary of the research presented by a panel of three experts at the virtual webcast symposium conference hosted by PeerVoice on 20th May 2021.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.